Contact Us
  • Choose License Type

Rest of the World Factor VIII Deficiency Treatment Market, by Product Type (Plasma Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Biologic (Hemlibra), and Desmopressin), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (Latin America, Asia Pacific, Middle East & Russia, and Africa), was valued at US$ 2,039.4 million in 2018, and is expected to exhibit a CAGR of 4.7%, over the forecast period (2019-2027).

Increasing incidence & prevalence of hemophilia is expected to drive growth of factor VIII deficiency treatment market over the forecast period. For instance, according to the World Federation of Hemophilia (WFH) 2018 statistics, there were around 440,000 people globally, who suffered from hemophilia, of which around 173,000 people were diagnosed with hemophilia A or B in 2017. Major players are focused on product or drug launches and approvals, owing to the rising demand of factor VIII deficiency treatment. For instance, in March 2016, U.S. Food and Drug Administration approved Kedrion’s, Koate Double Viral Inactivation (DVI) Antihemophilic Factor (human) with Mix2Vial, for the treatment of factor VIII deficiency. Moreover, in May 2018, Chugai Pharmaceutical Co., Ltd., a subsidiary of Roche Group launched its anticoagulation factor IXa/X humanized biospecific monoclonal antibody/ coagulation factor VIII substitute, HEMLIBRA for routine prophylaxis, to prevent or reduce the frequency of bleeding episodes in patients with congenital factor VIII deficiency (hemophilia A) with factor VIII inhibitors.

Browse 40 Market Data Tables and 25 Figures spread through 273 Pages and in-depth TOC on ‘Factor VIII Deficiency Treatment Market’- rest of the world forecast to 2027, by Product Type (Plasma Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Biologic (Hemlibra), and Desmopressin), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (Latin America, Asia Pacific, Middle East & Russia, and Africa)

To know the latest trends and insights prevalent in the Factor VIII Deficiency Treatment Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/rest-of-the-world-factor-viii-deficiency-treatment-market-3257

Asia Pacific is expected to offer lucrative market opportunity in the factor VIII deficiency treatment market over the forecast period, owing to the favorable regulatory scenario and guidelines by the government authorities, which is expected to fuel growth of the market over the forecast period. For instance, according to the World Hemophilia Foundation’s 2015 report of National Tenders for Purchase of Clotting Factor Concentrates, in Brazil the purchase of clotting factor concentrates has to be approved and licensed by the Brazilian Health Surveillance Agency (ANVISA), which is the national authority for product regulation and inspection. Moreover, several major players in the market are focusing on collaborations with an aim to develop novel therapies for the deficiency treatment, which is expected to facilitate growth of the market over the forecast period. For instance, in August 2018, RCSI, a Dublin-based international health sciences institution, and Bayer AG entered into a research collaboration to develop new treatment options for people with severe hemophilia. Furthermore, in May 2017, Sangamo Therapeutics, Inc. a genomic medicine company, and Pfizer Inc., entered into a global collaboration and license agreement for development and commercialization of a gene therapy based product for the treatment of hemophilia A.

Key Takeaways of the Factor VIII Deficiency Treatment Market:

  • The rest of the world factor VIII deficiency treatment market is expected to exhibit a CAGR of 4.7% over the forecast period, owing to rising cases of hemophilia and approvals and launches of novel products and drugs. For instance, according to National Hemophilia Foundation 2018 report, one in 10,000 people are born with hemophilia A due to deficiency of clotting factor VIII and one in 50,000 people are born with hemophilia B due to lack of clotting factor IX
  • Among product type, plasma derived coagulation factor concentrates segment held dominant position in the factor VIII deficiency treatment market in 2018, owing to cost effectivity. For instance, according to the reports published by the World Federation of Hemophilia in 2016, the demand for plasma derived coagulation factors is high as compared to recombinant coagulation concentrate due to its easy availability in emerging economies and affordable prices.
  • Companies operating in the rest of the world factor VIII deficiency treatment market include Baxter International, Inc., Biogen, Inc., Bayer AG, CSL Behring, Ferring B.V., F. Hoffmann-La Roche AG, Pfizer, Inc., Kedrion, and Novo Nordisk A/S.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner